Vivoryon Therapeutics’ glutaminyl cyclase inhibitor has failed a second phase 2 Alzheimer’s disease study this year, leaving ...

Vivoryon's VIVA-MIND trial echoed the disappointing Alzheimer’s findings of its VIVIAD trial but offers promise in treating ...

Dysregulated cell signaling underlies various diseases, emphasizing the importance of understanding these pathways for ...

The present study highlights the potential neuroprotective effects of certain classes of anticancer drugs (antimetabolites, multikinase inhibitors, and EGFR inhibitors) against Alzheimer's disease ...

Specifically, lower activation of the epidermal growth factor receptor (EGFR) signaling pathway occurs following reduced endocytosis. Decreased EGFR pathway activity allows LECs to switch from ...

They found both previously known and novel mutations significantly linked to EGFR activation and drug response, demonstrating the method's precision and revealing new pathways affecting tumor ...

VIVA-MIND Phase 2 data confirm results of varoglutamstat’s benefit on eGFR in VIVIAD; Company now has two independent double-blind placebo-controlled Phase 2 studies demonstrating a clinically ...

Vivoryon Therapeutics N.V. Reports Q3 2024 Results and Highlights Progress on Varoglutamstat in Kidney Disease Varoglutamstat Phase 2 program shows highly consistent, statistically significant and cli ...

A new BLA for Dato-DXd targets EGFR-mutated NSCLC, following withdrawal of a previous application based on TROPION-Lung01 trial data. The new submission is supported by phase 2 TROPION-Lung05 trial ...

Analysis of kidney function data revealed a statistically significant improvement of >4mL/min/1.73m 2 in the estimated glomerular filtration rate (eGFR) in patients treated with varoglutamstat ...